Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial
暂无分享,去创建一个
P. Serruys | R. D. de Winter | J. Wykrzykowska | S. Garg | S. Windecker | M. Valgimigli | K. Huber | R. V. van Geuns | P. Steg | A. Zurakowski | C. Hamm | P. Chichareon | R. Modolo | Kuniaki Takahashi | N. Kogame | Chun-Chin Chang | M. Tomaniak | P. Vranckx | Y. Onuma | P. Buszman | C. Tumscitz | M. Vrolix | C. Liebetrau | K. Żmudka | I. Petrov | M. Dominici | M. Ferrario | L. Bolognese | A. Aminian | E. Benit | L. Janssens | Norihiro Kogame
[1] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[2] M. Stoel,et al. Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial , 2017, JAMA cardiology.
[3] J. W. Louwerenburg,et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial , 2016, The Lancet.
[4] P. Serruys,et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] J. McMurray,et al. Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review , 2016, Circulation. Heart failure.
[6] L. Räber,et al. External validity of the “all-comers” design: insights from the BIOSCIENCE trial , 2016, Clinical Research in Cardiology.
[7] D. Shaw. HEAT-PPCI sheds light on consent in pragmatic trials , 2014, The Lancet.
[8] Mike Fisher,et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.
[9] S. Kaul,et al. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). , 2013, Journal of the American College of Cardiology.
[10] David Moher,et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa , 2012, Systematic Reviews.
[11] R. Little,et al. The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.
[12] Gordon H Guyatt,et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review , 2012, BMJ : British Medical Journal.
[13] P. Serruys,et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.
[14] G. Guyatt,et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.
[15] Fredrik Folke,et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.
[16] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[17] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.
[18] P. Kirchhof,et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.
[19] F. Eberli,et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.
[20] Richard Beasley,et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? , 2006, Thorax.
[21] M. Simoons,et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. , 2006, European heart journal.
[22] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[23] Kenneth F Schulz,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward , 2022 .